Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Decrease of cocaine, but not heroin, self-administration and relapse by the tyrosine kinase inhibitor masitinib in male Sprague Dawley rats.

Belin-Rauscent A, Lacoste J, Hermine O, Moussy A, Everitt BJ, Belin D.

Psychopharmacology (Berl). 2018 May;235(5):1545-1556. doi: 10.1007/s00213-018-4865-0. Epub 2018 Mar 8.

2.

Dual protein kinase and nucleoside kinase modulators for rationally designed polypharmacology.

Hammam K, Saez-Ayala M, Rebuffet E, Gros L, Lopez S, Hajem B, Humbert M, Baudelet E, Audebert S, Betzi S, Lugari A, Combes S, Letard S, Casteran N, Mansfield C, Moussy A, De Sepulveda P, Morelli X, Dubreuil P.

Nat Commun. 2017 Nov 10;8(1):1420. doi: 10.1038/s41467-017-01582-5.

3.

Integrated time-lapse and single-cell transcription studies highlight the variable and dynamic nature of human hematopoietic cell fate commitment.

Moussy A, Cosette J, Parmentier R, da Silva C, Corre G, Richard A, Gandrillon O, Stockholm D, Páldi A.

PLoS Biol. 2017 Jul 27;15(7):e2001867. doi: 10.1371/journal.pbio.2001867. eCollection 2017 Jul.

4.

ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?

Petrov D, Mansfield C, Moussy A, Hermine O.

Front Aging Neurosci. 2017 Mar 22;9:68. doi: 10.3389/fnagi.2017.00068. eCollection 2017. Review.

5.

Combination of imaging flow cytometry and time-lapse microscopy for the study of label-free morphology dynamics of hematopoietic cells.

Cosette J, Moussy A, Paldi A, Stockholm D.

Cytometry A. 2017 Mar;91(3):254-260. doi: 10.1002/cyto.a.23064. Epub 2017 Mar 1.

6.

Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study.

Lortholary O, Chandesris MO, Bulai Livideanu C, Paul C, Guillet G, Jassem E, Niedoszytko M, Barete S, Verstovsek S, Grattan C, Damaj G, Canioni D, Fraitag S, Lhermitte L, Georgin Lavialle S, Frenzel L, Afrin LB, Hanssens K, Agopian J, Gaillard R, Kinet JP, Auclair C, Mansfield C, Moussy A, Dubreuil P, Hermine O.

Lancet. 2017 Feb 11;389(10069):612-620. doi: 10.1016/S0140-6736(16)31403-9. Epub 2017 Jan 7.

7.

Exposome-Explorer: a manually-curated database on biomarkers of exposure to dietary and environmental factors.

Neveu V, Moussy A, Rouaix H, Wedekind R, Pon A, Knox C, Wishart DS, Scalbert A.

Nucleic Acids Res. 2017 Jan 4;45(D1):D979-D984. doi: 10.1093/nar/gkw980. Epub 2016 Oct 24.

8.

Rapid and clinically significant response to masitinib in the treatment of mucosal primary esophageal melanoma with somatic KIT exon 11 mutation involving brain metastases: A case report.

Prosvicova J, Lukesova S, Kopecky J, Grim J, Papik Z, Kolarova R, Navratilova B, Dubreuil P, Agopian J, Mansfield C, Moussy A, Hermine O.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015 Dec;159(4):695-7. doi: 10.5507/bp.2015.061. Epub 2015 Nov 27.

9.

Single Cell Dynamics Causes Pareto-Like Effect in Stimulated T Cell Populations.

Cosette J, Moussy A, Onodi F, Auffret-Cariou A, Neildez-Nguyen TM, Paldi A, Stockholm D.

Sci Rep. 2015 Dec 9;5:17756. doi: 10.1038/srep17756.

10.

A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer.

Deplanque G, Demarchi M, Hebbar M, Flynn P, Melichar B, Atkins J, Nowara E, Moyé L, Piquemal D, Ritter D, Dubreuil P, Mansfield CD, Acin Y, Moussy A, Hermine O, Hammel P.

Ann Oncol. 2015 Jun;26(6):1194-200. doi: 10.1093/annonc/mdv133. Epub 2015 Apr 9.

11.

Neuroprotective effect of masitinib in rats with postischemic stroke.

Kocic I, Kowianski P, Rusiecka I, Lietzau G, Mansfield C, Moussy A, Hermine O, Dubreuil P.

Naunyn Schmiedebergs Arch Pharmacol. 2015 Jan;388(1):79-86. doi: 10.1007/s00210-014-1061-6. Epub 2014 Oct 26.

12.

Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial.

Adenis A, Blay JY, Bui-Nguyen B, Bouché O, Bertucci F, Isambert N, Bompas E, Chaigneau L, Domont J, Ray-Coquard I, Blésius A, Van Tine BA, Bulusu VR, Dubreuil P, Mansfield CD, Acin Y, Moussy A, Hermine O, Le Cesne A.

Ann Oncol. 2014 Sep;25(9):1762-9. doi: 10.1093/annonc/mdu237. Epub 2014 Jul 25.

13.

Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study.

Vermersch P, Benrabah R, Schmidt N, Zéphir H, Clavelou P, Vongsouthi C, Dubreuil P, Moussy A, Hermine O.

BMC Neurol. 2012 Jun 12;12:36. doi: 10.1186/1471-2377-12-36.

14.

Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.

Georgin-Lavialle S, Lhermitte L, Suarez F, Yang Y, Letard S, Hanssens K, Feger F, Renand A, Brouze C, Canioni D, Asnafi V, Chandesris MO, Aouba A, Gineste P, Macintyre E, Mansfield CD, Moussy A, Lepelletier Y, Dubreuil P, Hermine O.

Eur J Haematol. 2012 Jul;89(1):47-52. doi: 10.1111/j.1600-0609.2012.01761.x. Epub 2012 Apr 28.

PMID:
22324351
15.

Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy.

Moura DS, Sultan S, Georgin-Lavialle S, Pillet N, Montestruc F, Gineste P, Barete S, Damaj G, Moussy A, Lortholary O, Hermine O.

PLoS One. 2011;6(10):e26375. doi: 10.1371/journal.pone.0026375. Epub 2011 Oct 21.

16.

Masitinib decreases signs of canine atopic dermatitis: a multicentre, randomized, double-blind, placebo-controlled phase 3 trial.

Cadot P, Hensel P, Bensignor E, Hadjaje C, Marignac G, Beco L, Fontaine J, Jamet JF, Georgescu G, Campbell K, Cannon A, Osborn SC, Messinger L, Gogny-Goubert M, Dubreuil P, Moussy A, Hermine O.

Vet Dermatol. 2011 Dec;22(6):554-64. doi: 10.1111/j.1365-3164.2011.00990.x. Epub 2011 Jun 13.

PMID:
21668810
17.

Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial.

Piette F, Belmin J, Vincent H, Schmidt N, Pariel S, Verny M, Marquis C, Mely J, Hugonot-Diener L, Kinet JP, Dubreuil P, Moussy A, Hermine O.

Alzheimers Res Ther. 2011 Apr 19;3(2):16. doi: 10.1186/alzrt75.

18.

Masitinib as a chemosensitizer of canine tumor cell lines: a proof of concept study.

Thamm DH, Rose B, Kow K, Humbert M, Mansfield CD, Moussy A, Hermine O, Dubreuil P.

Vet J. 2012 Jan;191(1):131-4. doi: 10.1016/j.tvjl.2011.01.001. Epub 2011 Feb 17.

PMID:
21333567
19.

Safety of masitinib mesylate in healthy cats.

Daly M, Sheppard S, Cohen N, Nabity M, Moussy A, Hermine O, Wilson H.

J Vet Intern Med. 2011 Mar-Apr;25(2):297-302. doi: 10.1111/j.1939-1676.2011.0687.x. Epub 2011 Feb 11.

20.

Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study.

Paul C, Sans B, Suarez F, Casassus P, Barete S, Lanternier F, Grandpeix-Guyodo C, Dubreuil P, Palmérini F, Mansfield CD, Gineste P, Moussy A, Hermine O, Lortholary O.

Am J Hematol. 2010 Dec;85(12):921-5. doi: 10.1002/ajh.21894.

21.

Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors.

Hahn KA, Legendre AM, Shaw NG, Phillips B, Ogilvie GK, Prescott DM, Atwater SW, Carreras JK, Lana SE, Ladue T, Rusk A, Kinet JP, Dubreuil P, Moussy A, Hermine O.

Am J Vet Res. 2010 Nov;71(11):1354-61. doi: 10.2460/ajvr.71.11.1354. Erratum in: Am J Vet Res. 2011 Feb;72(2):247.

PMID:
21034327
22.

Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer.

Mitry E, Hammel P, Deplanque G, Mornex F, Levy P, Seitz JF, Moussy A, Kinet JP, Hermine O, Rougier P, Raymond E.

Cancer Chemother Pharmacol. 2010 Jul;66(2):395-403. doi: 10.1007/s00280-010-1299-8. Epub 2010 Apr 4.

PMID:
20364428
23.

Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).

Le Cesne A, Blay JY, Bui BN, Bouché O, Adenis A, Domont J, Cioffi A, Ray-Coquard I, Lassau N, Bonvalot S, Moussy A, Kinet JP, Hermine O.

Eur J Cancer. 2010 May;46(8):1344-51. doi: 10.1016/j.ejca.2010.02.014. Epub 2010 Mar 6.

PMID:
20211560
24.

Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model.

Humbert M, Castéran N, Letard S, Hanssens K, Iovanna J, Finetti P, Bertucci F, Bader T, Mansfield CD, Moussy A, Hermine O, Dubreuil P.

PLoS One. 2010 Mar 4;5(3):e9430. doi: 10.1371/journal.pone.0009430.

25.

Drug-induced minimal change nephropathy in a dog.

Sum SO, Hensel P, Rios L, Brown S, Howerth EW, Driskell EA, Moussy A, Hermine O, Brown CA.

J Vet Intern Med. 2010 Mar-Apr;24(2):431-5. doi: 10.1111/j.1939-1676.2010.0471.x. No abstract available.

26.

Masitinib for the treatment of canine atopic dermatitis: a pilot study.

Daigle J, Moussy A, Mansfield CD, Hermine O.

Vet Res Commun. 2010 Jan;34(1):51-63. doi: 10.1007/s11259-009-9332-2. Epub 2009 Dec 23.

PMID:
20033487
27.

Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations.

Bodemer C, Hermine O, Palmérini F, Yang Y, Grandpeix-Guyodo C, Leventhal PS, Hadj-Rabia S, Nasca L, Georgin-Lavialle S, Cohen-Akenine A, Launay JM, Barete S, Feger F, Arock M, Catteau B, Sans B, Stalder JF, Skowron F, Thomas L, Lorette G, Plantin P, Bordigoni P, Lortholary O, de Prost Y, Moussy A, Sobol H, Dubreuil P.

J Invest Dermatol. 2010 Mar;130(3):804-15. doi: 10.1038/jid.2009.281. Epub 2009 Oct 29.

28.

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.

Dubreuil P, Letard S, Ciufolini M, Gros L, Humbert M, Castéran N, Borge L, Hajem B, Lermet A, Sippl W, Voisset E, Arock M, Auclair C, Leventhal PS, Mansfield CD, Moussy A, Hermine O.

PLoS One. 2009 Sep 30;4(9):e7258. doi: 10.1371/journal.pone.0007258.

29.

Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics.

Humbert M, de Blay F, Garcia G, Prud'homme A, Leroyer C, Magnan A, Tunon-de-Lara JM, Pison C, Aubier M, Charpin D, Vachier I, Purohit A, Gineste P, Bader T, Moussy A, Hermine O, Chanez P.

Allergy. 2009 Aug;64(8):1194-201. doi: 10.1111/j.1398-9995.2009.02122.x.

PMID:
19614621
30.

Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study.

Tebib J, Mariette X, Bourgeois P, Flipo RM, Gaudin P, Le Loët X, Gineste P, Guy L, Mansfield CD, Moussy A, Dubreuil P, Hermine O, Sibilia J.

Arthritis Res Ther. 2009;11(3):R95. doi: 10.1186/ar2740. Epub 2009 Jun 23.

31.

Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers.

Soria JC, Massard C, Magné N, Bader T, Mansfield CD, Blay JY, Bui BN, Moussy A, Hermine O, Armand JP.

Eur J Cancer. 2009 Sep;45(13):2333-41. doi: 10.1016/j.ejca.2009.05.010. Epub 2009 Jun 21.

PMID:
19541476
32.

Pharmacokinetics of masitinib in cats.

Bellamy F, Bader T, Moussy A, Hermine O.

Vet Res Commun. 2009 Dec;33(8):831-7. doi: 10.1007/s11259-009-9231-6.

PMID:
19533403
33.

Masitinib is safe and effective for the treatment of canine mast cell tumors.

Hahn KA, Ogilvie G, Rusk T, Devauchelle P, Leblanc A, Legendre A, Powers B, Leventhal PS, Kinet JP, Palmerini F, Dubreuil P, Moussy A, Hermine O.

J Vet Intern Med. 2008 Nov-Dec;22(6):1301-9. doi: 10.1111/j.1939-1676.2008.0190.x. Epub 2008 Sep 24. Erratum in: J Vet Intern Med. 2009 Jan-Feb;23(1):224. Oglivie, G [corrected to Ogilvie, G].

34.

Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors.

Letard S, Yang Y, Hanssens K, Palmérini F, Leventhal PS, Guéry S, Moussy A, Kinet JP, Hermine O, Dubreuil P.

Mol Cancer Res. 2008 Jul;6(7):1137-45. doi: 10.1158/1541-7786.MCR-08-0067.

35.

Case-control cohort study of patients' perceptions of disability in mastocytosis.

Hermine O, Lortholary O, Leventhal PS, Catteau A, Soppelsa F, Baude C, Cohen-Akenine A, Palmérini F, Hanssens K, Yang Y, Sobol H, Fraytag S, Ghez D, Suarez F, Barete S, Casassus P, Sans B, Arock M, Kinet JP, Dubreuil P, Moussy A.

PLoS One. 2008 May 28;3(5):e2266. doi: 10.1371/journal.pone.0002266.

36.

Phenotypic and genotypic characteristics of mastocytosis according to the age of onset.

Lanternier F, Cohen-Akenine A, Palmerini F, Feger F, Yang Y, Zermati Y, Barète S, Sans B, Baude C, Ghez D, Suarez F, Delarue R, Casassus P, Bodemer C, Catteau A, Soppelsa F, Hanssens K, Arock M, Sobol H, Fraitag S, Canioni D, Moussy A, Launay JM, Dubreuil P, Hermine O, Lortholary O; AFIRMM network.

PLoS One. 2008 Apr 9;3(4):e1906. doi: 10.1371/journal.pone.0001906.

Supplemental Content

Loading ...
Support Center